Mural Oncology (MURA) to Release Earnings on Tuesday

Mural Oncology (NASDAQ:MURA) is projected to announce its earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($1.68) per share for the quarter.

Mural Oncology (NASDAQ:MURA) last issued its earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same quarter last year, the business posted ($3.57) EPS. On average, analysts expect Mural Oncology to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Mural Oncology Stock Up 1.5 %

Shares of NASDAQ MURA opened at $2.63 on Friday. The business’s 50 day moving average price is $2.46 and its two-hundred day moving average price is $3.27. The company has a market cap of $45.41 million, a PE ratio of -0.29 and a beta of 3.91. Mural Oncology has a twelve month low of $0.95 and a twelve month high of $4.74.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on MURA shares. HC Wainwright dropped their price target on Mural Oncology from $18.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, March 26th. Raymond James cut shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 target price for the company. in a research note on Tuesday, March 25th. Morgan Stanley lowered shares of Mural Oncology from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, March 25th. Finally, Jones Trading restated a “hold” rating on shares of Mural Oncology in a report on Tuesday, March 25th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $13.00.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.